Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hawthorn Pharmaceuticals has said that the FDA has approved granisol oral solution for the prevention of nausea and vomiting associated with cancer therapy.
Subscribe to our email newsletter
Granisol is the AA-rated equivalent of Roche’s Kytril oral solution. Granisol oral solution is available through all the national drug wholesalers as well as multiple other distribution channels and will begin shipping immediately. Granisol oral solution is available by prescription only in the US.
Chris Smith, vice president of sales at Hawthorn, said: “We feel this product will fill an important need in helping to prevent nausea and vomiting associated with chemotherapy or radiation for cancer therapy patients who may have difficulty swallowing tablets.”